Aurora Spine (ASG) Q4 2024 earnings summary

Executive summary

• Fiscal 2024 revenue increased 21% year-over-year to $17.6 million, driven by proprietary products and a strengthened internal sales force.

• Achieved first full-year positive EBITDA/EBITDAC of $0.28 million, with significant margin improvement and strong product adoption, especially for SiLO TFX.

• Key leadership promotions and expansion of the sales team to 14 people supported growth and market penetration.

• Net loss for FY 2024 was $1.00 million, improved from $1.68 million in 2023.

• Gross margin increased to 60.5% in 2024 from 56.5% in 2023, driven by higher sales of proprietary products and lower inventory costs.

Financial highlights

• Q4 2024 revenue was $4.7 million, up 16.3% from Q4 2023; full-year revenue reached $17.56 million, up from $14.52 million in 2023.

• Gross margin improved to 57.8% in Q4 2024 (from 56.7%) and 60.5% for FY 2024 (from 56.5%).

• Operating expenses for FY 2024 were $11.44 million, including $1.11 million non-cash, up from $9.89 million in 2023.

• FY 2024 EBITDA/EBITDAC was $0.28 million, a turnaround from -$0.31 million in 2023; Q4 EBITDA/EBITDAC was -$0.32 million, impacted by IFRS fair value accounting and increased training expenses.

• Ended Q4 with $826K in cash; receivables reduced to below $500K, with most under 30 days.

Outlook and guidance

• Expects continued year-over-year revenue growth in 2025, with annual revenue growth budgeted at least 20%.

• Anticipates strong 2025 performance, driven by the launch of the AERO facet fusion system, with initial surgeries expected in H2 2025.

• Focus remains on achieving full cash flow positivity in 2025, with ongoing investments in training and product launches.

• Plans to continue expanding the sales force and focus on commercialization over R&D.

• Anticipates best Q1 in company history, despite typical seasonality.